T he ubiquity and impact of non communicable diseases such as cardiovascular diseases, type 2 diabetes, cancers, chronic obstruc tive pulmonary disease, and psy chiatric disorders present major global health, development, and societal challenges. 1 Acknowledg ing this fact, the United Nations (UN) General Assembly will hold a highlevel meeting on global noncommunicable diseases on September 19 and 20, 2011, in New York. The movement to rec ognize and address the preven tion and control of global non communicable diseases in this way undoubtedly drew some inspira tion from a 2001 UN summit that produced a "Declaration of Com mitment" on the human immuno deficiency virus (HIV) and AIDS, generating awareness and resourc es, and propelling collective global action to confront the HIV-AIDS pandemic. 2 And indeed, the expe rience with HIV-AIDS offers les sons that may apply to the initia tive for noncommunicable diseases.
In the early days of HIV-AIDS, the U.S. Centers for Disease Con trol and Prevention and the World Health Organization emphasized disease surveillance to draw at tention to the problem and im prove our understanding of the growing magnitude, demograph ics, and cost of the epidemic. At the same time, the U.S. National Institutes of Health and others sought to understand the biology of the disease and to find effec tive therapies and preventive ap proaches, often necessarily sup porting research in geographic areas where the disease was high ly prevalent. There was also pres sure to deliver solutions expedi ently, to which the U.S. Food and Drug Administration responded by initiating a paralleltrack ap proval process. Several powerful activist groups, motivated by the inevitable fatality of HIV-AIDS, launched influential advocacy campaigns, which drew active and vocal participation from physi cians, medical societies, high profile celebrities, and affected groups. These advocacy efforts garnered major resources in the form of the U.S. President's Emer gency Plan for AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which committed billions of dollars from many highincome countries to fight these diseases globally (see graphs).
HIV is a transmissible infection with identifiable behavioral risk factors; it leads to a chronic debili tating disease that is fatal in the absence of early detection and ef fective treatment. Over the years, experts on HIV-AIDS have come to accept three realities: the search for cause and cure and the fight against the pandemic must be global rather than national; pre vention must inevitably be linked to early diagnosis and treatment, which means that approaches must be developed that effectively con nect community resources with or ganized health care systems; and although behavior plays a major role in risk for HIV, prevention ef forts need to integrate both behav ioral and biomedical approaches -for example, promoting con dom use and advances in bio medical interventions (e.g., micro bicides, preexposure prophylaxis, and treatment as prevention) are complementary in reducing inci dence.
Taking lessons from the HIV-AIDS experience and applying them well could shorten the learning curve for noncommuni cabledisease prevention and con trol. Good surveillance systems for noncommunicable diseases and their risk factors are crucial for measuring the magnitude of the problem and its associated costs, identifying vulnerable sub groups, and evaluating the ef fects of policy and practice inter ventions, especially in low and middleincome countries where such data are woefully lacking. Serious global commitments to basic and applied research are essential; research is currently overwhelmingly concentrated in highincome countries, but the burden of noncommunicable dis eases is felt around the globe. Indeed, these diseases often dis proportionately affect low and middleincome countries and fre quently strike young and middle aged people who are at the peak of their economic productivity. Conducting research only in high income countries neglects the possibilities of elucidating vari ability in the causes of and risk for noncommunicable diseases among populations worldwide, of enabling high and lowincome countries to learn from each other, and of leveraging global resources in the development of lowcost, contextually appropriate behav ioral, diagnostic, and biomedical interventions. 3 Although some ef fective interventions exist for pre venting and controlling these dis eases, implementation is often sadly inadequate worldwide; that's where comparative applied and operational research conducted internationally and integrating both social and biomedical sci ences can help by providing im portant data on metrics of real life, populationlevel effectiveness, such as the reach, adoption, and sustainability of interventions.
Undoubtedly, combating non communicable diseases will re quire concerted action to advance sciencedriven public health in terventions (e.g., the reduction of tobacco and transfat use) and healthfriendly international and national policies in areas ranging from trade and agriculture to transportation and urban plan ning. At the same time, the HIV-AIDS experience may guide the linking of detection, prevention, and treatment and the integration of behavioral and biomedical ap proaches that are just as applicable to noncommunicable diseases. 4 For example, hypertension, type 2 dia betes, and prediabetes remain un Annual no. of AIDS-related deaths 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 detected in large proportions of people worldwide (in low, middle, and highincome countries alike), and lowcost detection approaches should be linked to wide imple mentation of proven costeffective strategies for prevention and treat ment that efficiently integrate pub lic health, community, and health care resources. As in HIV-AIDS, although be haviors (such as eating an un healthy diet and being physically inactive) are potent risk factors for cardiovascular disease and type 2 diabetes, the best available lifestyle interventions are insuffi cient on their own and mainly affect the most motivated adopt ers, leaving large groups of peo ple at risk who can benefit from proven biomedical interventions (e.g., generic statins, antihyperten sive and antidiabetic medications, or aspirin). Therefore, although the rigorous pursuit of evidence based behavioral interventions and societal policies that facili tate healthier lifestyles must con tinue, it is critical to welcome and integrate the use of lowcost biomedical interventions into pre vention efforts for noncommuni cable diseases, viewing them as complementary and part of a ho listic approach. 5 In the case of HIV-AIDS, there has been overwhelming de mand from the public and clini cians worldwide for broad avail ability of treatments and effective chronic care; such demand will also grow in the area of noncom municable diseases. Without ac cessible interventions for early treatment and control, societies end up paying far more for thera pies for advanced disease -a challenge that will inevitably be posed by the epidemic of non communicable diseases. The win dow of opportunity for implement ing effective care and preventive services will therefore simultane ously require prioritizing the de velopment of delivery and financ ing models for integrated health systems and ensuring that sup plies (of essential medicines, for example) meet the demand. Iron ically, the lack of good health systems for noncommunicable dis eases in many low and middle income countries may offer op portunities for testing innovative models in ways that cannot be done in highincome countries with mature systems. The Khay alitsha antiretroviraldrug pro gram spearheaded by Médecins sans Frontières in South African townships and the experiences of the Aravind Eye Care Hospitals in India are good examples of what can be achieved through the innovative organization of low cost human capital and technol ogy in lowerincome countries.
HIV-AIDS has also taught us the value of societal engagement: successful programs have active ly involved the affected commu nities, harnessed the goodwill and support of highprofile ce lebrities, and energized advocacy and political support and will. Above all, we have learned that the fight against diseases such as HIV-AIDS is global and that so lutions can emerge from any where. The importance of both HIV-AIDS and noncommunicable diseases was initially recognized in highincome countries, but these diseases affect all coun tries; they may therefore inspire increased global collaboration in research and public health action.
The UN summit offers a rare opportunity to generate momen tum and resources for tackling global noncommunicable diseas es. The challenges are daunting, but as the experience with HIV-AIDS has demonstrated, solutions are feasible.
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